Patient‐reported outcomes
nausea, dyspnea, diarrhea, constipation, insomnia
For the EORTC‐QLQ‐C30 scales, chi‐square tests of differences in proportions of responders revealed that most patients remained stable across most symptoms and QoL scores over the first three cycles. Significant differences in proportions of patients with improved, deteriorated, or stable scores were observed for several symptom scales for at least one cycle, including constipation, diarrhea, dyspnea, nausea and vomiting, and insomnia. Similarly, most patients remained stable with respect to their cognitive functioning and reported no change in financial difficulties during one or more cycles. For PROMIS F, no significant differences were found in the proportion of patients by responder type (improved, deteriorated, and stable). Trends showed most patients remained stable across all three cycles. Contrary to trends observed for the EORTC‐QLQ‐C30 and PROMIS F scores, overall health status measured by the EQ‐5D, worsened for a larger proportion of patients, but this was not consistent across all cycles. In summary, physical functioning, key symptoms, and overall health status scores from the EORTC‐QLQ‐C30 and PROMIS F remained stable for most patients across the first three post‐baseline cycles. Similarly, for cognitive function and symptom scores of the EORTC‐QLQ‐C30, most patients remained stable during one or more cycles.